VKORC1
ENSG00000167397
Target class
Enzyme
Chromosome
16
Approved drugs
5
Clinical candidates (approved and in development)
7
- Approved drugs
- 5
- ClinGen gene-disease validity
- Moderate
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- VKORC1
- Gene name
- Vitamin K epoxide reductase complex subunit 1
- Gene symbol
- VKORC1
- Previous gene symbols
- VKCFD2
- Protein name
- Vitamin K epoxide reductase complex subunit 1 (EC 1.17.4.4) (Vitamin K1 2,3-epoxide reductase subunit 1)
- Gene biotype
- Protein coding
- Gene family
- Vitamin K epoxide reductase complex subunit 1 family
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 306.7
- Tissue specificity (Gini)
- 0.338
- Tissue specificity (tau)
- 0.669
- KEGG gene identifiers
- hsa:79001
- Reactome pathways
- R-HSA-6806664
- Protein interaction confidence
- 0.848684
- Protein interaction partners
- 19
- End position
- 31095980
- Start position
- 31090842
- Chromosome
- 16
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Multi-pass membrane protein .
- Endoplasmic reticulum
- PubMed 14765194
- PubMed 15716279
- PubMed 16270630
- PubMed 20978134
- PubMed 22923610
- PubMed 20696932
- PubMed 33154105
- Tissue specificity (tau)
- 0.669298
- Expression inequality (Gini)
- 0.338218
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 306.7
- Artery - Aorta
- 269.24
- Liver
- 244.21
- Artery - Coronary
- 211.48
- Cervix - Ectocervix
- 190.45
Expression in transcripts per million
- Cells - Cultured fibroblasts306.7
- Artery - Aorta269.24
- Liver244.21
- Artery - Coronary211.48
- Cervix - Ectocervix190.45
- Uterus186.88
- Artery - Tibial182.94
- Cervix - Endocervix182.58
- Ovary178.47
- Pituitary171.05
- Nerve - Tibial162.95
- Fallopian Tube148.86
- Bladder136.87
- Esophagus - Gastroesophageal Junction133.5
- Vagina128.97
- Colon - Sigmoid127.86
- Thyroid127.63
- Adipose - Subcutaneous123.59
- Adipose - Visceral (Omentum)117.93
- Lung117.59
- Esophagus - Muscularis116.99
- Breast - Mammary Tissue116.4
- Adrenal Gland112.42
- Prostate110.68
- Minor Salivary Gland105.57
And 29 more, listed on the interactive page.
- GO:0006805
- GO:0007596
- GO:0017187
- GO:0042373
- GO:0005783
- GO:0005789
- GO:0005515
- GO:0047057
- GO:0047058
Related records
Trials (552)
- "ORBIT" Versus "HAS-BLED" Scores in Predicting Major Bleeding in Patients With Atrial Fibrillation Receiving Oral Anticoagulants.
- 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
- A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions
- A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
- A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
- A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers
- A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
- A Dose Response Study of Dabigatran Etexilate(BIBR 1048) in Pharmacodynamics and Safety in Patients With Non-valvular Atrial Fibrillation in Comparison to Warfarin
- A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers
- A Drug Interaction Study of Danicopan
- A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers
- A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
- A Drug Interaction Study With Albiglutide and Warfarin
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Drug-Drug Interaction Study Between AZD9668 and Warfarin to Study the Effect of AZD9668 on the Metabolism and Effect of Warfarin
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
- A Drug-Drug Interaction Study of Warfarin and PA21
Drugs (8)
- Acenocoumarol Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Dicumarol Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Phenindione Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Phenprocoumon Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Tecarfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Warfarin Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Warfarin potassium Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- Warfarin sodium Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor